© 2000 American Heart Association, Inc.
Thrombosis |
Reduced Thrombus Formation by Hyaluronic Acid Coating of Endovascular Devices
From the Division of Molecular Medicine(S.V., C.P.M., K.A.R., N.A.F.C., S.R.H.), Yerkes Regional Primate Research Center, Departments of Medicine (S.V., M.Y.S., S.B.K., S.R.H.) and Biomedical Engineering (C.P.M., S.R.H.), Emory University School of Medicine, Atlanta, Ga; Genzyme Corporation (B.W.), Cambridge, Mass; and The Atlanta Cardiovascular Research Institute (K.A.R., N.A.F.C.), Atlanta, Ga.
Correspondence to Stephen R. Hanson, PhD, 1639 Pierce Dr, Room 1129 WMB, Emory University, Atlanta, GA 30322. E-mail shanson{at}emory.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Biocompatible stent coatings may alleviate problems of increased (sub)acute thrombosis after stent implantation. Hyaluronic acid (HA), a ubiquitous, nonsulfated glycosaminoglycan, inhibits platelet adhesion and aggregation and prolongs bleeding when administered systemically. However, the effects of immobilized HA for reducing stent platelet deposition in vivo are unknown. We therefore quantified the antithrombotic effects of coating stainless steel stents and tubes with HA using an established baboon thrombosis model under physiologically relevant blood flow conditions. HA-coated and uncoated (control) stents (3.5 mm in diameter, n=32) and stainless steel tubes (4.0 mm in diameter, n=18) were deployed into exteriorized arteriovenous shunts of conscious, nonanticoagulated baboons. Accumulation of 111In-radiolabeled platelets was quantified by continuous gamma-camera imaging during a 2-hour blood exposure period. HA coating resulted in a significant reduction in platelet deposition in long (4 cm) tubes (0.24±0.15x109 versus 6.12±0.49x109 platelets; P<0.03), short (2 cm) stainless steel tubes (0.18±0.06x109 versus 3.03±0.56x109 platelets; P<0.008), and stents (0.82±0.20x109 versus 1.83±0.23x109 platelets; P<0.02) compared with uncoated control devices. Thus, HA coating reduces platelet thrombus formation on stainless steel stents and tubes in primate thrombosis models. These results indicate that immobilized HA may represent an attractive strategy for improving the thromboresistance of endovascular devices.
Key Words: thrombosis • stents • hyaluronic acid • baboon
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Stent thrombosis results from a series of complex interactions involving the presence of a thrombogenic surface, the damaged vascular wall, altered blood flow, and the activation of platelets and coagulation proteins.1 The effectiveness of antiplatelet agents in reducing thrombosis in atherosclerotic disease has been demonstrated with aspirin and clopidogrel.2 3 Ticlopidine has been shown to reduce periprocedural thrombotic events in coronary stenting to 1% to 2% in low- and intermediate-risk groups.4 5 However, the incidence of stent thrombosis is substantially increased in higher-risk patients.6 In addition, aspirin and ticlopidine may produce significant side effects.7 These findings suggest a need for further improvements in antithrombotic strategies associated with coronary stenting.
Coating stents with biocompatible and nonthrombogenic materials is an attractive alternative for further reducing (sub)acute stent thrombosis. A number of different stent coatings have been evaluated previously.8 9 10 11 12 13 Results with these coatings, including antithrombotic agents and components of cell membranes (biomimicry), appear promising, although larger studies and more cost-effective coatings are needed.14 15
Hyaluronic acid (HA) is a ubiquitous, nonsulfated glycosaminoglycan component of the extracellular matrix. Both HA and immobilized sulfated HA have been shown to inhibit platelet aggregation and platelet adhesion, as well as to prolong bleeding-time measurements when administered systemically.16 17 However, the effects of HA coating of stents on in vivo platelet reactions are presently unknown. The objective of this study was to assess in primates the effects of HA coating on platelet thrombus formation on metallic tubes and stents under controlled and physiologically relevant conditions of blood flow and exposure time.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
All procedures were approved by the Institutional Animal Care and Use Committee in compliance with National Institutes of Health guidelines (Guide for the Care and Use of Laboratory Animals, 1985).
Coated Stents and Tubes
Stainless steel tubes and stents were coated with HA (molecular
weight 1 to 3x106 Da) by Genzyme
Corporation. Briefly, HA was covalently immobilized
onto plasma-treated 316L stainless steel tubes (Small Parts, Inc) (2
and 4 cm long; 4 mm ID) and stents (Multilink, ACS Guidant)
(15 mm long and 3.5 mm in diameter) with water-soluble
carbodiimide, as described previously.18
Baboon Thrombosis Model
Devices were deployed into exteriorized arteriovenous (AV)
shunts in baboons. The chronic AV shunts were composed of silicone
rubber tubing (3-mm ID, Dow Corning) placed between the baboon femoral
artery and vein. Sixteen juvenile male baboons (Papio
anubis/cynocephalus) weighing 9 to 12 kg were studied. The animals
were quarantined and observed to be disease free for 
3 months.
Platelet deposition was measured with
111In-labeled platelets as previously
described.19 In brief, autologous baboon
platelets were labeled with 1 mCi of
111In-oxine. The accumulation of
111In-labeled platelets was measured
continuously with a gamma scintillation camera (General Electric 400T).
Data were stored at 5-minute intervals and analyzed with a
computer-assisted image-processing system interfaced with the camera.
We calculated the total number of deposited platelets by dividing
the deposited platelet radioactivity (counts per minute) by the
whole-blood 111In-platelet activity (counts
per min/mL) and multiplying by the circulating platelet count
(platelets per milliliter).19
Coated and uncoated stainless steel stents were fully deployed with 3.5-mm noncompliant angioplasty balloons (ACS Guidant) at 10 atm into silicone rubber tubing of 3.2 mm ID. Stainless steel tubes (4.0-mm ID) were interposed between segments of 4.0-mm ID silicone rubber tubing. The tubing segments were prefilled with sterile saline, connected to the AV shunt, and maintained at arterial flow rates (100 mL/min) for 120 minutes without systemic anticoagulation.
Scanning Electron Microscopy
After blood exposure, the stents and steel tubes were
disconnected from the shunt, flushed gently with sterile saline, filled
with 2.5% buffered glutaraldehyde for 15 minutes, and
then filled with 0.1 mol/L cacodylate and stored at 4°C until further
processing. Metallic tubes were opened longitudinally with a milling
bit and drill press. The stents were carefully removed from the rubber
tubing and delicately opened longitudinally with surgical scissors.
Scanning electron microscopy (SEM) was performed as described
previously.20
Statistical Analysis of Data
Data are presented as mean±SEM. Statistical comparisons
were performed with Sigma-Stat (Jandel Scientific). Two-way ANOVA was
used to analyze the effects of HA coating and time on
platelet deposition between the HA-coated stents or steel tubes
versus the uncoated controls. The unpaired Student’s t test
was used for comparisons between treated and control groups.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
AV Shunt Studies
Eighteen stainless steel tubes (9 coated and 9 uncoated) and 32 stents (8 coated and 24 uncoated) were studied. The measurements of platelet deposition on the stainless steel tubes are shown in Figure 1
. For the 2-cm-long tubes,
platelet deposition on the controls increased during the first 80
minutes of the study, then either plateaued or occluded the tube
(Figure 1A). The HA coating significantly reduced platelet
deposition (by 94% versus controls;
0.18±0.06x109 versus
3.03±0.56x109 platelets;
P<0.008). In the 4-cm-long stainless steel tubes (Figure 1B), platelet deposition was reduced by 96% versus the
controls (0.24±0.15x109 versus
6.12±0.49x109 platelets;
P<0.03). Platelet deposition was directly proportional
to the area of exposed metal surface, because in the control studies,
twice as many platelets deposited on the 4-cm tubes than on the
2-cm tubes.
|
As shown in Figure 2, HA coating of
stents reduced platelet deposition by 55% after 2 hours of blood
exposure (0.82±0.20x109 versus 1.83±0.23
x 109 platelets; P<0.02). This
reduction was significantly greater at earlier time points (75%
reduction at 1 hour; P<0.0001).
|
Macroscopy and SEM
Thrombus was grossly evident on both uncoated steel tubes and
uncoated stents but was virtually absent on the HA-coated tubes and
less apparent on the HA-coated stents (Figure 3, A through D). By SEM, uncoated
stainless steel tubes (Figure 3E) showed substantial adherent
mixed thrombus (erythrocytes, leukocytes, platelets, and fibrin).
In contrast, the HA-coated tubes displayed a smooth luminal surface
with occasional adherent red cells and leukocytes (Figure 3F).
The uncoated stents also accumulated mixed thrombus, which covered the
entire stent surface in a continuous layer (Figure 3, C and G).
In contrast, HA-coated stents had only small isolated thrombi, composed
typically of dendritic platelets, which accumulated primarily at
areas of stent strut convergence (Figure 3, D and H).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Stent thrombosis remains an important problem despite improvements in stent deployment techniques and the use of aspirin and ticlopidine or clopidogrel. The incidence of stent thrombosis is between 0.6% and 2.2% for low-risk patients undergoing elective stenting,4 21 but in higher-risk patients, it is 5.6%.6 One approach to this problem is to coat stents with an immobilized antithrombotic agent.
HA, a high-molecular-weight nonsulfated glycosaminoglycan, is a ubiquitous component of extracellular matrix22 and has been shown to inhibit platelet aggregation and adhesion16 and to prolong the bleeding time at high concentrations.17 Because of its antithrombotic effects and its known coating abilities,17 23 24 HA may provide a potential biocompatible and thromboresistant coating for endovascular devices. The baboon AV shunt model was used to assess coated tubes and stents because this test system allows for exposure of metal surfaces to nonanticoagulated blood under arterial blood flow conditions. Additionally, the chronic shunt does not activate platelets or coagulation without an inserted metal surface.25 In this model, HA coating significantly reduced platelet deposition versus the results with uncoated control devices.
For stainless steel tubes, HA coating reduced platelet thrombus by >94% after 2 hours of blood exposure compared with uncoated tubes (P<0.03). For stainless steel stents, HA coating resulted in a similar reduction of platelet deposition (75% at 1 hour; P<0.0001) compared with uncoated stents. The amount of platelet deposition seen in the uncoated stents and tubes was consistent with previous stent evaluations in this model.8 10 26 27 28 29 Platelet deposition in the stainless steel tubes was also directly proportional to lumenal surface area for the 2- and 4-cm-long tubes. This result is important because it indicates that (1) stainless steel is inherently thrombogenic, and (2) thrombus forms uniformly and reproducibly for tubular devices having relatively small dimensions. Control tubes (2-cm longx4.0-mm ID) showed somewhat higher platelet deposition than control stents (1.5-mm long; deployed into 3.2-mm-ID tubing), a finding that can be attributed in part to the greater metallic surface area of the tubes versus the stents.
Interestingly, although thrombus accumulation on the HA-treated tubes
was effectively abolished (Figure 1
), the HA-treated stents
still accumulated some thrombus (P=0.033 at 120 minutes,
HA-treated stents versus HA-treated 2-cm tubes). The remarkable
effectiveness of HA for abolishing platelet deposition on the
smooth-walled tubes is probably explained by (1) HA coverage of the
thrombogenic metallic surface, (2) the absence of surface
irregularities that could serve as sites for thrombus attachment and
growth, and (3) the rapid dilution under unidirectional laminar blood
flow of procoagulant and platelet activating factors, such as
thrombin. Similarly, the observations that HA coating reduced thrombus
accumulation to a lesser degree on stents than on smooth-walled tubes
is presumably due to stent geometric irregularities (stent struts),
which can generate regions of flow recirculation and stasis, leading to
localized blood coagulation, platelet activation, thrombus
attachment, and thrombus growth. Thus, whereas uncoated stents and
tubes accumulated considerable gross thrombus, HA-coated stents showed
only small isolated thrombi at the areas of stent strut convergence
(Figure 3), which suggests that flow disturbances may
indeed contribute to thrombus formation in this setting. This finding
is also consistent with other observations with this model
showing that smooth surfaces tend to be less thrombogenic than textured
or irregular devices.19
Previous studies with other stent coatings (eg, phosphorylcholine and
heparin) using the same experimental model have shown similar effects
for reducing platelet deposition.8 10 However, there
is sparse information on the stability and longevity of these
alternative coating materials. Immobilized HA was found to
be stable for 2 months in PBS at 37°C as demonstrated by x-ray
photoelectron spectroscopy, Fourier-transformed infrared spectroscopy,
and glucosamine assays.27 In addition,
immobilized HA is significantly resistant to
hyaluronidase digestion.27
The baboon model, as used in the present study, is advantageous because the effects of stent-related variables are emphasized. However, the model differs from human stent applications in several important respects. First, the stents were assessed in an ex vivo shunt system rather than in native arteries, thereby excluding the possible effects of both prothrombotic and antithrombotic components of the vessel wall. Second, no pharmacological inhibitors of platelets or coagulation were administered in the present study, although antithrombotic therapy is commonly administered to stent recipients clinically. In previous baboon studies, stent thrombus formation was reduced by oral aspirin and clopidogrel28 but not by systemic heparin.29 For clinical applications, it seems likely that thrombus formation on HA-coated stents could be reduced by antiplatelet therapy as well.
Thus, our results may not directly predict clinical efficacy. Nonetheless, primates are hemostatically similar to humans, and immobilized HA significantly reduced platelet deposition on both thrombogenic stainless steel tubes and clinical endovascular stents. This study, the first to document such effects in vivo, suggests that additional studies with immobilized HA are warranted to assess this thromboresistant material as a coating for stents and other cardiovascular devices.
|
Acknowledgments |
|---|
This study was supported in part by research grants HL31469 and RR-00165 (Yerkes Regional Primate Research Center) from the National Institutes of Health; by the ERC Program of the National Science Foundation under award EEC-9731643; and by a grant from Genzyme Corporation, Cambridge, Mass. The technical assistance of Evan Dessasau, Deborah White, and Steven Marzec is greatly appreciated.
|
Footnotes |
|---|
Genzyme Corporation is a manufacturer of hyaluronic acid.
Received November 29, 1999; accepted January 27, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol. 1987;60:20B–28B.[Medline] [Order article via Infotrieve]
2.
Collaborative overview of randomised trials of
antiplatelet therapy, I: prevention of death, myocardial
infarction, and stroke by prolonged antiplatelet therapy in various
categories of patients: Antiplatelet Trialists’
Collaboration. BMJ. 1994;308:81–106.
3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.[Medline] [Order article via Infotrieve]
4.
Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini
R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt
C, Ulm K. A randomized comparison of antiplatelet and anticoagulant
therapy after the placement of coronary-artery stents.
N Engl J Med. 1996;334:1084–1089.
5. Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, Fajadet J, Gaspard P, Glatt B, Joly P. Intracoronary stenting without coumadin: one month results of a French multicenter study. Cathet Cardiovasc Diagn. 1995;35:1–7.[Medline] [Order article via Infotrieve]
6.
Urban P, Macaya C, Rupprecht HJ, Kiemeneij F,
Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L.
Randomized evaluation of anticoagulation versus antiplatelet
therapy after coronary stent implantation in high-risk
patients: the Multicenter Aspirin and Ticlopidine Trial after
Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126–2132.
7.
Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C,
Roth G. Aspirin and other platelet-active drugs: the relationship
among dose, effectiveness, and side effects. Chest. 1995;108:247S–257S.
8. Chronos NAF, Robinson KA, Kelly AB, Taylor A, Yianni J, King SB III, Harker LA, Hanson SR. Thromboresistant phosphorylcholine coating for coronary stents. Circulation. 1995;95(suppl I):I-685. Abstract.
9. Matsuhashi T, Miyachi H, Ishibashi T, Sakamoto K, Yamadera A. In vivo evaluation of a fluorine-acryl-stylene-urethane-silicone antithrombogenic coating material copolymer for intravascular stents. Acad Radiol. 1996;3:581–588.[Medline] [Order article via Infotrieve]
10. Chronos NAF, Robinson KA, King SB III, Lunn A, White D, Kelly AB, Harker LA. Heparin coated Palmaz-SchatzTM stents are highly thrombo-resistant: a baboon A-V shunt study. J Am Coll Cardiol. 1996;27:84A. Abstract.
11.
De Scheerder I, Wang K, Wilczek K, Meuleman D, Van
Amsterdam R, Vogel G, Piessens J, Van de Werf F. Experimental study of
thrombogenicity and foreign body reaction induced by heparin-coated
coronary stents. Circulation. 1997;95:1549–1553.
12. Alt E, Seliger C. Antithrombotic stent coatings: hirudin/iloprost combination. Semin Interv Cardiol. 1998;3:177–183.[Medline] [Order article via Infotrieve]
13.
Maalej N, Albrecht R, Loscalzo J, Folts JD. The potent
platelet inhibitory effects of S-nitrosated
albumin coating of artificial surfaces. J Am Coll
Cardiol. 1999;33:1408–1414.
14. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673–681.[Medline] [Order article via Infotrieve]
15. Cumberland DC, Gunn J, Malik N, Holt CM. Biomimicry 1: PC. Semin Interv Cardiol. 1998;3:149–150.[Medline] [Order article via Infotrieve]
16. Barbucci R, Ito Y, Favia P. New materials containing HyalSx. Soc Biomaterials Trans. 1998;21:171. Abstract.
17.
Mitchell JD, Lee R, Hodakowski GT, Neya K, Harringer W,
Valeri CR, Vlahakes GJ. Prevention of postoperative pericardial
adhesions with a hyaluronic acid coating solution: experimental safety
and efficacy studies. J Thorac Cardiovasc Surg. 1994;107:1481–1488.
18. Hamilton R, Fox EM, Acharya RA, Walts AE. Water insoluble derivatives of hyaluronic acid. US Patent No. 4,937,270. June 26, 1990.
19. Harker LA, Kelly AB, Hanson SR. Experimental arterial thrombosis in nonhuman primates. Circulation. 1991;83(suppl IV):IV-41–IV-55.
20. Robinson KA, Roubin G, King S, Siegel R, Rodgers G, Apkarian RP. Correlated microscopic observations of arterial responses to intravascular stenting. Scanning Microsc. 1989;3:665–678; discussion 678–679.[Medline] [Order article via Infotrieve]
21.
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho
KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ,
Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens
after coronary-artery stenting: Stent Anticoagulation
Restenosis Study Investigators. N Engl J
Med. 1998;339:1665–1671.
22. Entwistle J, Hall CL, Turley EA. HA receptors: regulators of signalling to the cytoskeleton. J Cell Biochem. 1996;61:569–577.[Medline] [Order article via Infotrieve]
23. Urman B, Gomel V, Jetha N. Effect of hyaluronic acid on postoperative intraperitoneal adhesion formation in the rat model. Fertil Steril. 1991;56:563–567.[Medline] [Order article via Infotrieve]
24. Hagberg L, Gerdin B. Sodium hyaluronate as an adjunct in adhesion prevention after flexor tendon surgery in rabbits. J Hand Surg. 1992;17:935–941.[Medline] [Order article via Infotrieve]
25. Harker LA, Hanson SR. Experimental arterial thromboembolism in baboons: mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979;64:559–569.
26. Scott NA, Robinson KA, Nunes GL, Thomas CN, Viel K, King SB, Harker LA, Rowland SM, Juman I, Cipolla GD, Hanson SR. Comparison of the thrombogenicity of stainless steel and tantalum coronary stents. Am Heart J. 1995;129:866–872.[Medline] [Order article via Infotrieve]
27. Wan B, McGregor H, Clavin M, Chang G, Shiedlin A, Nickerson CMB, Skinner K, Chronos NAF, Verheye S, Robinson KA, Hanson SR. Evaluation of immobilized hyaluronic acid: stability and platelet deposition studies. Soc Biomaterials Trans. 1999;22:228. Abstract.
28.
Harker LA, Marzec UM, Kelly AB, Chronos NAF, Sundell
IB, Hanson SR, Herbert J-M. Clopidogrel inhibition of stent, graft, and
vascular thrombogenesis with antithrombotic enhancement by aspirin in
non-human primates. Circulation. 1998;98:2461–2469.
29. Krupski WC, Bass A, Kelly AB, Marzec UM, Hanson SR, Harker LA. Heparin-resistant thrombus formation by endovascular stents in baboons. Circulation. 1990;81:570–577.
This article has been cited by other articles:
 |
|
 |
|
  E. R. Tamm, R. G. Carassa, D. M. Albert, B. T. Gabelt, S. Patel, C. A. Rasmussen, and P. L. Kaufman Viscocanalostomy in Rhesus Monkeys Arch Ophthalmol, December 1, 2004; 122(12): 1826 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Kolodgie, A. P. Burke, A. Farb, D. K. Weber, R. Kutys, T. N. Wight, and R. Virmani Differential Accumulation of Proteoglycans and Hyaluronan in Culprit Lesions: Insights Into Plaque Erosion Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1642 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Andrew, P. Monagle, G. deVeber, and A. K.C. Chan Thromboembolic Disease and Antithrombotic Therapy in Newborns Hematology, January 1, 2001; 2001(1): 358 - 374. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||